We present the case of a 33-year-old female with a 4.3 × 3.2 cm high-density mass in the apical segment of the right upper lobe, detected on non-contrast chest CT, which showed suspected invasion of the chest wall and other tissues. CT-guided lung biopsy confirmed lung adenocarcinoma, and genetic testing revealed an EGFR exon 19 deletion. The patient received neoadjuvant therapy with oral Osimertinib combined with chemotherapy. After 4 months of treatment, she underwent thoracoscopic right upper lobectomy, mediastinal lymph node dissection, and pleural adhesion lysis. Postoperative management included anti-infection therapy, expectorants, nebulization, and analgesia. The patient recovered well and was discharged on postoperative day five, with good general condition at follow-up. This case illustrates that neoadjuvant targeted therapy combined with chemotherapy can convert locally unresectable lung cancer to a resectable status and improve operative feasibility, thus offering valuable insights for clinical management.
Lin et al. (Tue,) studied this question.